Cannabis
Psilera to Present Innovative New Clinical & Technological Progress at the Psychedelic Capital Virtual Event
Tampa, Florida–(Newsfile Corp. – August 31, 2021) – Psilera Inc., a private biotechnology company specializing in the clinical development of psychedelics and analogues, is pleased to share the latest corporate updates as the company continues to develop new formulations and technology using psychedelic compounds.
The next edition of the psychedelic investment series will be Today, Tuesday, August 31, 2021, at 1:30 PM EST.
The Psychedelic Capital Investment Conference is dedicated to providing investment grade information for the nascent psychedelic sector and presents a curated group of CEOs, financial experts, thought leaders and investment luminaries from around the globe.
Each month, the #PsyCap features the top companies, latest IPOs, newest opportunities and deepest insights into the emerging psychedelic space. Investment thought leaders and wealth influencers provide our audiences with valuable insights. C-suite company executives covering every corner of the psychedelics industries, media and financial services companies are available to speak one on one. This is a must-attend for investors.
We are excited to present Psilera Inc., a leading biotechnology company with a diversified drug pipeline encompassing formulations, new psychedelic analogues, and next-generation technology to hasten clinical development. With a proven and award-winning executive team, Psilera leverages research strengths from the pharmaceutical and cannabis industries to repurpose psychoactive natural products into innovative new treatment options for mental health patients around the world. Their protectable new formulations are able to tailor the therapeutic effects of DMT leading to improved treatment scalability and patient compliance. Furthermore, Psilera’s team of computational chemists are continuing to make significant progress on a proprietary software platform called BRAIN. BRAIN will leverage advanced informatics and chemistry to identify new chemical entities with modified psychedelic and therapeutic effects for the treatment of mental health conditions.
For more information and/or to register for the conference please visit: https://microdose.buzz/
We look forward to seeing you there.
For further information, please contact:
Chris Witowski, PhD
[email protected]
www.psilera.com
About Microdose Psychedelic Insights
Microdose Psychedelic Insights aims to unlock the potential of psychedelics through Industry events, market intelligence, original, evidence-based content, strategy and community. We enable and empower society at large to make better, more mindful decisions about psychedelics and its intersection with healthcare, medicine and personal growth. We work with the industry’s most influential stakeholders, some of the world’s best-known brands and an unrivalled network of scientists, researchers, analysts, innovators, investors and advisors.
About PsyCap
This online event programming is dedicated to providing investment grade information for the nascent psychedelic sector and presents a curated group of CEOs, financial experts, thought leaders and investment luminaries from around the globe. Presentations are 30 minutes in length, with 10 minutes always allocated to a one-on-one Q&A session with the audience. Psychedelic Capital features the top companies, latest IPOs, newest opportunities and deepest insights into the emerging psychedelic space.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94525
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Innocan2 weeks ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf2 weeks ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis2 weeks ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
SCHWAZZE4 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis4 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt4 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis4 days ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical